

María de la Fuente Freire, PhD, is co-founder and CEO/CSO of DIVERSA, a nanomedicine spin-off born from the Galician public health system (IDIS–SERGAS) in Santiago de Compostela, Spain. She leads the Nano-Oncology and Translational Therapeutics group at IDIS, where she has spent more than one decade working on lipid-based drug delivery. Her research focuses on translating nanoparticle platforms into clinical therapies, with an emphasis on mRNA and gene delivery for oncology. This work underpins DIVERSA's patented technology and its lead clinical asset, a first-in-class local mRNA immunotherapy for cancer. She holds a PhD in Nanomedicine from the University of Santiago de Compostela, and trained as a researcher at the University of Kuopio, University of Valladolid and University College London – School of Pharmacy.